Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML
口服酪蛋白激酶 1α 和细胞周期蛋白依赖性激酶 7/9 抑制剂 BTX-A51 治疗晚期 MDS 和 AML 的 I 期首次人体剂量递增研究
期刊:
影响因子:
doi:10.21203/rs.3.rs-4954060/v1
Brian Ball, Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam, Guido Marcucci, Anthony Stein, Dung Luong Thai, David Cook, Kyle Chan, Sonali Persaud, Ross Levine, Omar Abdel-Wahab, Yinon Ben-Neriah, Eytan Stein